IUPAC/Chemical Name
Piperidine, 1-(3-(3-(aminoiminomethyl)phenyl)-2-(((4-methylphenyl)sulfonyl)amino)-1-oxopropyl)-
InChi Key
RNNMXTSTLVYYQG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N4O3S/c1-16-8-10-19(11-9-16)30(28,29)25-20(22(27)26-12-3-2-4-13-26)15-17-6-5-7-18(14-17)21(23)24/h5-11,14,20,25H,2-4,12-13,15H2,1H3,(H3,23,24)
SMILES Code
O=C(N1CCCCC1)C(NS(=O)(C2=CC=C(C)C=C2)=O)CC3=CC=CC(C(N)=N)=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
428.55
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Zesławska E, Jacob U, Stürzebecher J, Oleksyn BJ. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate. Bioorg Med Chem Lett. 2006 Jan 1;16(1):228-34. Epub 2005 Oct 3. PubMed PMID: 16202591.
2: Turk D, Stürzebecher J, Bode W. Geometry of binding of the N alpha-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes. FEBS Lett. 1991 Aug 5;287(1-2):133-8. PubMed PMID: 1879520.
3: Hauptmann J, Markwardt F, Richter M. [Animal experiments on the pharmacokinetics of N alpha-tosyl-(3-amidinophenyl)alanine piperidide (TAPAP), a new thrombin inhibitor]. Pharmazie. 1982 Jun;37(6):430-3. German. PubMed PMID: 7122685.
4: Bergner A, Bauer M, Brandstetter H, Stürzebecher J, Bode W. The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity. J Enzyme Inhib. 1995;9(1):101-10. PubMed PMID: 8568562.
5: Henriques ES, Fonseca N, Ramos MJ. On the modeling of snake venom serine proteinase interactions with benzamidine-based thrombin inhibitors. Protein Sci. 2004 Sep;13(9):2355-69. PubMed PMID: 15322279; PubMed Central PMCID: PMC2280023.
6: Glusa E, Hoffmann A, Markwardt F. Influence of benzamidine derivatives on thrombin-induced platelet reactions. Folia Haematol Int Mag Klin Morphol Blutforsch. 1982;109(1):98-106. PubMed PMID: 6177615.
7: Hauptmann J. Degradation of a benzamidine-type synthetic inhibitor of coagulation enzymes in plasma of various species. Thromb Res. 1991 Feb 1;61(3):279-84. PubMed PMID: 2028446.
8: Mills JE, Perkins TD, Dean PM. An automated method for predicting the positions of hydrogen-bonding atoms in binding sites. J Comput Aided Mol Des. 1997 May;11(3):229-42. PubMed PMID: 9263850.
9: Markwardt F, Nowak G, Hoffmann J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb Haemost. 1983 Jun 28;49(3):235-7. PubMed PMID: 6603675.
